Webinar
B2C2B in Digital Health, a founder's playbook
- U.S. out-of-pocket health spending is projected to rise from nearly $500 billion in 2021 to approximately $800 billion by 2026.
- The B2C2B model enables startups to bypass initial payer contracts by acquiring and engaging users directly, using evidence of 100 to 1,000 active employees or members to facilitate enterprise entry.
- Virtual care is maturing into a standard clinical service, allowing companies to invert growth strategies toward direct-to-consumer acquisition while securing traditional payer reimbursement.
- Early consumer engagement accelerates product-market fit through user retention iteration and helps shorten enterprise sales cycles by demonstrating momentum.
- High engagement and stickiness across both consumer and business segments are expected to create a resilient business model with long-term defensibility.
- Successful early consumer acquisition relies on understanding user information-seeking behaviors to lower costs, supported by marketing strategies that have generated approximately 20,000 email addresses through brand partnerships.
- Companies must build a "minimum chassis" that is minimally HIPAA compliant to prevent the distribution of unverified medical recommendations, even if specific services do not strictly require it.
- Narrow targeting of academic researcher groups, with expectations that 10 to 100 deeply addicted users can justify logical expansion to larger populations, is advised before broad implementation.
- Cash pay models offer reduced friction but risk limiting chargeable amounts and creating consumer confusion regarding insurance expectations, whereas subscription models trade initial purchase friction for natural usage patterns.
- Pricing strategies prioritize B2C engagement over revenue, while B2B buyers generally prefer simplicity; payers typically favor per-member-per-month pricing, whereas employers often prefer annual licenses.
- Enterprise buyers, including health systems requiring ROI or break-even guarantees, expect randomized controlled trials demonstrating impact, such as six-month outcomes showing reduced fall rates, or large-scale user volume to validate impact data.
- Butterfly established a $2,000 price point for its device based on clinician affordability and global viability, while adding enterprise security and governance features to secure higher recurring SaaS revenue.
- The most critical metric for enterprise buyers is the number of active users rather than complex cost-saving calculations, necessitating that feature additions do not increase friction or reduce engagement.
- Professional services may be deployed for up to 18 months across 2,000 individuals at 20 sites to ensure implementation success, serving as a guarantee of software utility rather than a workaround for product deficiencies.
- Investors, including A16Z, seek validation of both consumer and enterprise motions early in the trajectory, looking for high product velocity, a pipeline of enterprise logos, and preferably live contracts.
- Enterprise entry requires storytelling around scale and care pathway integration, with financial ROI rationalized post-implementation, and requires conservative commitments from engineering teams to avoid over-promising.
- A16Z anticipates the B2C2B approach will improve healthcare outcomes and lower costs, requiring build plans that accommodate parallel investment in two distinct business motions.